Evaluación de la intervención en paciente diabético en la farmacia comunitaria (zona urbana en Valladolid durante el periodo de abril a junio del 2021)

  1. Valles Martín, Elena 1
  2. Mateos Rodríguez, Elena 1
  3. Treceño Lobato, Carlos 1
  4. Melgar Vicente, María José 2
  1. 1 Farmacia Ldo. Treceño Lobato
  2. 2 Farmacia Melgar
Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2022

Volume: 7

Issue: 1

Pages: 39-51

Type: Article

DOI: 10.14201/FJ2022713951 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

Diabetes mellitus is a chronic disease with a prevalence in the Spanish population of 6.8?%, 96.6?% of which is type II diabetes mellitus. Taking this disease as a major health problem, the aim of this study is the proactive search from the pharmacy office for problems related to medication or negative results of medications in order to solve them and improve their quality of life. In the first phase, patients were screened for inclusion in the study and then surveys were carried out to collect the information necessary for the work. Thanks to the results we obtained, we were able to see that many patients had DRPs and NRMs that could be remediable if detected, such as insufficiently treated health problems, potential interaction, or likelihood of adverse effects. In addition, the patient treated with metformin monotherapy was more likely to suffer adverse reactions or drug derived DRPs. Thus, the pharmacist’s intervention in the detection and resolution of these problems leads to the improvement of the diabetic patient’s quality of life.

Bibliographic References

  • Al-Musawe L, Torre C, Guerreiro JP, Teixeira Rodrigues A, Raposo JF, Mota-Filipe M, Martin AP. Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacol Res Perspect. 2020.
  • Alonso-Morán E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marqués González ML, Toro Polanco N, Ezkurra Loiola P, Gaztambide S, Nuño-Solinis R. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC. 2014.
  • Artime E, Romera I, Díaz-Cerezo S, Delgado E. Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review. Diabetes Ther. 2021 Jun; 12(6):1631-1659.
  • Bukhsh A, Khan TM, Shaun W. H. Lee, Learn-Han Lee, Kok-Gan Chan, Bey-Hing Goh. Efficacy of Pharmacist Based Diabetes Educational Interventions on Clinical Outcomes of Adults with Type 2 Diabetes Mellitus: A Network Meta-Analysis Front Pharmacol. 2018 Apr 10; 9:339.
  • Jiménez Serranía MI, Treceño Lobaco C, Martínez García R, Corzo-Delibes F, Martin Arias LH. Unidad 4: Hormonas y agentes relacionados. En: Manual de farmacología básica para ciencias de la salud. Valladolid: Servicio de publicaciones de la UEMC; 2019.
  • Luque del Moral R. Atención farmacéutica del paciente diabético. Farmacia comunitaria como centro sanitario para el control de estos pacientes. Revista Trimestral Farmacéuticos Comunitarios. 2014; 6. (suplemento 1) [Internet] [consultado el 20 de mayo de 2021]. Disponible: https://www.farmaceuticoscomunitarios.org/es/journal-article/atencion-farmaceutica-integral-del-paciente-diabetico-farmacia-comunitaria.
  • Mabel Maidana G, Vera Z, Samaniego L, Acosta P, Mastroianni P, Lugo GB. SciELO. [Internet] Madrid: Ars Pharmaceutical; 2017 [actualizado 13 mayo de 2020; citado 20 de mayo de 2021]. Disponible en: https://scielo.isciii.es/pdf/ars/v58n1/2340-9894-ars-58-1-21.pdf.
  • Mendes Moura A, Oliveira Martins S, Raposo JF. Consumption of antidiabetic medicines in Portugal: results of a temporal data analysis of a thirteen year study (2005-2017). BMC Endocr Disord. 2021.
  • Moreno Juste A, Menditto E, Orlando V, Monetti VM, Gimeno Miguel A, González Rubio F, Pascual-Salcedo A MM, Cahir C, Prados Torres A, Riccardi G. Treatment Patterns of Diabetes in Italy: A Population-Based Study. Front Pharmacol. 2019.
  • Moulis G, Ibáñez B, Palmaro A, Aizpuru F, Millán E, Lapeyre-Mestre M, Sailler L, Cambra K. Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus. Clin Epidemiol. 2018.
  • Nogueira M, Jun Otuyama L, Alves Rocha P, Barbosa Pinto V. et al. Pharmaceutical care-based interventions in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials Einstein (São Paulo). 2020.
  • Zhuang Y, Song J, Ying M, Li M. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis Medicine. 2020.
Data source: Dialnet